MIM Software Inc., a leading global provider of medical imaging software, announced today new innovations to MIM SurePlan™ MRT, its software package for Molecular Radiotherapy.
The MIM SurePlan MRT has been deemed to meet EU safety, health and environmental protection requirements, thus receiving CE Mark approval for new artificial intelligence (AI) segmentation models. The implementation of AI simplifies the contouring process for dosimetry. This saves significant time and provides enhanced results compared to manual and atlas-based segmentation. In addition to the AI segmentation models, MIM SurePlan MRT includes two single timepoint methods – the Hänscheid approach and the prior-information approach.
The Hänscheid approach uses a single SPECT/CT acquired around a carefully chosen time after each cycle of therapy to calculate the absorbed dose. The prior information approach uses time-activity curve information from multiple SPECT/CTs after the first cycle to calculate the dose for the remaining cycles, using only a single SPECT/CT at each of the remaining cycles.
The mew methods ensure clinicians the ability to perform dosimetry in situations where it is not possible to obtain multiple SPECT/CTs for patients. The technology enhances patient care and provides customer-centered and innovative solutions.
“We’ve identified that two of the most common barriers for implementing clinical dosimetry are resource management and logistics around obtaining multiple image acquisitions,” said Tim Adams, Nuclear Medicine Market Director at MIM Software. “Our goal for these new additions to MIM SurePlan MRT is to make capturing dosimetry practical for both clinics and patients by removing some of the hurdles associated with conventional dosimetry approaches.”
The new AI segmentation models are not available in all countries. Chech with your local MIM Software representative for availability in your region.
